Stock Analysis
Teleflex IncorporatedTFX
Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
AnalystsHold19 analystsPrice is 72% of the way from the year's low to its high.
Cash covers 11% of debt · Q2 2026.
PMP Verdict
Weak fundamentals
Strengths
- Quality65
Risks
- Growth0
- Profitability17
Weak fundamentals — valuation is the only support.
What's happening with TFX
Profile
growth, profitability and valuation lag behind.
How is each axis scored?
- Valuation40/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (1.6%)5/25
- P/S (3.4x)20/25
- EV/EBIT (39.6x)5/25
- Growth0/100 · Weak
- Revenue CAGR (-8.2%)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability17/100 · Weak
- ROIC (2.9%)5/25
- ROE (-35.5%)0/25
- Net margin (-63.3%)0/25
- Operating margin (12.6%)12/25
- Financial Health50/100 · Moderate
- Altman Z (1.96)10/25
- Current ratio (2.60)25/25
- Interest coverage (2.6x)10/25
- Net cash / debt (D/A 38%)5/25
- Quality65/100 · Moderate
- Piotroski F (5/9)15/25
- Beneish M (-2.75)25/25
- FCF conversion (-9%)0/25
- Margin stability (σ 4.8%)25/25
- Moat50/100 · Moderate
- ROIC >12% years (0/10 yrs)0/25
- Median gross margin (55.3%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst -45.4%)0/25
Risk Flags
- ⚠Interest coverage 2.6× — thin debt cushion
- ⚠Revenue shrinking 8.2%/yr
About Teleflex Incorporated
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. Show more
It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.
Headquarters: WAYNE, PA · Employees: 15,500 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
40D+P/E (TTM)—
Price / TTM EPS (own statements)
P/FCF15.7xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield1.6%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -0.3%–8.9% · 6th pct
P/S (TTM)3.39xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 1.4x–6.9x · 43rd pct
EV/EBIT39.6xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 17.5x–650.8x · 95th pct
EV/Sales3.0xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E12.6xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio1.90xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio0.61A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield1.12%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio14.8%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
17EROIC2.9%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-35.5%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-14.5%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-63.3%D
Grade D: LowNet Income / Revenue
Operating Margin12.6%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin57.6%A
Grade A: PremiumGross Profit / Revenue
FCF Margin5.6%D
Grade D: LowFCF / Revenue
True FCF Margin4.1%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR-8.2%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-10.6%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.4%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
50CAltman Z-Score1.96C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.60xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio1.88xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage2.6xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment28.8yD
Grade D: SlowYears to repay net debt via FCF
Net Debt/EBIT12.7xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity1.01xC
Grade C: MedDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.11xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
65BPiotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.75A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion-8.8%D
Grade D: PoorFCF / Net Income
Margin Stability4.8%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue3.9%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.37xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Salmon Sean Filed | Salmon Sean | Grant / award | +4.4K | |
Salmon Sean Filed | Salmon Sean | Grant / award | +674 | |
Weidman Jason R. Filed | Weidman Jason R. | Grant / award | +26.1K | |
Weidman Jason R. Filed | Weidman Jason R. | Grant / award | +54.0K | |
RANDLE STUART A Filed | RANDLE STUART A | Grant / award | +2.2K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
RANDLE STUART A Filed | RANDLE STUART A | Grant / award | +4.7K | |
RANDLE STUART A Filed | RANDLE STUART A | Grant / award | +995 | |
RANDLE STUART A Filed | RANDLE STUART A | Tax withholding | -4054 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
50CROIC >12% Years0/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)55.3%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-45.4%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$7.08
Cash & short-term investments per share (Finnhub)
Book Value / Share$68.55
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$2.94B
Total debt obligations (short + long term)
Cash & Equiv.$323.94M
Cash and short-term investments
Net Debt$2.61B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$2.90B
Shareholders' equity (book value)
Asset / Liability1.75xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$5.53B
Current Market Capitalization
Beta0.85B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Teleflex Incorporated (TFX)
TFX is up 1.72% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Teleflex Incorporated. Altman Z-Score of 1.96 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of -2.75 suggests a low likelihood of earnings manipulation.
- Revenue has been contracting (CAGR ≈ -8%), which weighs on the growth outlook.
- Takes ~28.8 years to repay net debt from free cash flow.
- Teleflex Incorporated posted a net loss in 1 of 10 available completed fiscal years (2016–2025).
See how TFX ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all TFX moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 127.82 | +3.67% | 2.57 |
| Oct 15 | After-hours | 128.22 | +4.00% | 2.79 |
| Sep 28 | Regular | 127.05 | +4.08% | 4.20 |
| Sep 25 | Regular | 122.55 | +2.05% | 2.50 |
| Sep 25 | After-hours | 122.07 | +1.65% | 2.14 |
Frequently Asked Questions about TFX
What is the current Teleflex Incorporated (TFX) stock price?
TFX is trading at $130.43 at the last market close, up 1.72% on the session. PreMarketPrice tracks TFX pre-market, intraday and after-hours prices.
Is TFX stock a buy right now?
PreMarketPrice's quantitative model rates Teleflex Incorporated's financial health at 50/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is TFX stock overvalued?
Teleflex Incorporated trades at a trailing P/E of n/a and our valuation score rates it 40/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Teleflex Incorporated report earnings?
No confirmed earnings date is currently scheduled for TFX. The Earnings section lists recent reports and updates as dates are announced.
What sector does Teleflex Incorporated operate in?
Teleflex Incorporated operates in the Healthcare sector, within the Surgical & Medical Instruments & Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does Teleflex Incorporated do?
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs.
About Teleflex Incorporated (TFX) Stock
Teleflex Incorporated (TFX) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry. As of the latest update, Teleflex Incorporated is trading at $130.43, up 1.72% on the day with a market capitalization of $5.5 billion. The financial health score for TFX is 50/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for TFX stock.
TFX Stock Analysis & Key Metrics
On PreMarketPrice, you can track Teleflex Incorporated (TFX) across multiple dimensions:
- Pre-market price & movement: Real-time TFX stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for TFX with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Teleflex Incorporated across multiple reporting periods.
- Financial health score: A composite score of 50/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for TFX.
- Sector peers: Compare TFX against 6 other healthcare stocks on key financial metrics.
Is TFX a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Teleflex Incorporated (TFX) as an investment. The financial health score of 50/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Teleflex Incorporated (TFX) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.